Skip to main content

Advertisement

SpringerLink
Log in

Von der Alopecia areata bis zum metabolischen Syndrom

Psoriasis und Komorbidität

  • Zertifizierte Fortbildung
  • Published:
ästhetische dermatologie & kosmetologie Aims and scope

Zusammenfassung

Bei Patienten mit Psoriasis schränken häufig komorbide Störungen die Lebensqualität zusätzlich ein. Dazu tragen auch Stigmatisierung und Unverständnis gegenüber den Betroffenen bei. Ursache dafür sind vor allem die Äußerlich sichtbaren Erkrankungssymptome. Hier kann die Ästhetische Dermatologie entscheidend Einfluss nehmen, wenn sie in das Gesamtbehandlungskonzept der Psoriasis implementiert wird.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3
4
5
6

Literatur

  1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015; 386: 983–4

    Article  CAS  PubMed  Google Scholar 

  2. Augustin M et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 4:1–16

    Article  PubMed  Google Scholar 

  3. Schäfer I et al. Epidemiologie der Psoriasis in Deutschland — Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen. 2011;73: 308–13

    Article  PubMed  Google Scholar 

  4. Schmid-Ott G et al. Psychosoziale Folgen der Psoriasis — eine empirische Studie über die Krankheitslast bei 3753 Betroffenen. Hautarzt. 2005; 56: 466–72

    Article  CAS  PubMed  Google Scholar 

  5. Alpsoy E et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol. 2017; 44: 885–91

    Article  PubMed  Google Scholar 

  6. Hawro M et al. Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J Am Acad Dermatol. 2017; 76: 648–54

    Article  PubMed  Google Scholar 

  7. Masaki S et al. Treatment satisfaction, willingness to pay and quality of life in Japanese patients with psoriasis. J Dermatol. 2017; 44:143–6

    Article  PubMed  Google Scholar 

  8. Schöffski O et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: Amulit-centre study. JDDG. 2007; 3: 209–18

    Article  Google Scholar 

  9. Asahina A et al. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: long-term differential effects of biologics. J Dermatol. 2016; 43:779–84

    Article  CAS  PubMed  Google Scholar 

  10. Takata T et al. Detection of asymptomatic enthesitis in psoriasis patients: an onset of psoriatic arthritis? J Dermatol. 2016; 43: 650–4

    Article  CAS  PubMed  Google Scholar 

  11. Yamamoto T et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol. 2016; 43:1193–6

    Article  PubMed  Google Scholar 

  12. Yamamoto T et al. Prevalence and current therapies of psoriatic arthritis in Japan: a survey by the Japanese Society of Psoriasis Research in 2016. J Dermatol. 2017; 44: e121

    Article  PubMed  Google Scholar 

  13. Stuart PE et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015; 97: 816–36

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Reich K et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. BJD. 2009; 160: 1040–7

    Article  CAS  Google Scholar 

  15. Zachariae H et al. Quality of Life and Prevalence of Arthritis Reported by 5,795 Members of the Nordic Psoriasis Associations - Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002; 82: 108–13

    Article  PubMed  Google Scholar 

  16. Boehncke WH et al. Komorbiditäten bei Psoriasis vulgaris. Hautarzt 2009; 60: 116–21

    Article  PubMed  Google Scholar 

  17. Koch M et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol. 2015; 135: 1283–93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Parisi R et al. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol. 2015; 135: 2189–97

    Article  CAS  PubMed  Google Scholar 

  19. Lonnberg AS et al. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. JAMA Dermatol. 2016; 152: 761–7

    Article  PubMed  Google Scholar 

  20. Cohen AD et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008; 22: 585–9

    Article  CAS  PubMed  Google Scholar 

  21. Naito R, Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan: a hospital-based case-control study. J Dermatol. 2016; 43: 1406–11

    Article  PubMed  Google Scholar 

  22. Liu JH et al. Relation between endothelial progenitor cells and arterial stiffness in patients with psoriasis. J Dermatol. 2016; 43: 888–93

    Article  CAS  PubMed  Google Scholar 

  23. Honma M et al. Close correlation of bone mineral density and body mass index in Japanese psoriasis patients. J Dermatol. 2017; 44: e1–2

    Article  PubMed  Google Scholar 

  24. Chularojanamontri L et al. Metabolic syndrome and psoriasis severity in South-East Asian patients: an investigation of potential association using current and chronological assessments. J Dermatol. 2016; 43: 1424–8

    Article  PubMed  Google Scholar 

  25. Furue M et al. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. Intern Med. 2017; 56: 1613–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Oh EH et al. Epidemiology and cardiovascular comorbidities in patients with psoriasis: a Korean nationwide population-based cohort study. J Dermatol. 2017; 44: 621–9

    Article  PubMed  Google Scholar 

  27. Jacobi A et al. Prevalence of Obesity in Patients with Psoriasis: Results of the National Study PsoHealth3. Dermatology. 2015; 231: 231–8

    Article  PubMed  Google Scholar 

  28. Kim DS et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016; 43: 305–10

    Article  PubMed  Google Scholar 

  29. Pina T et al. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-a therapy. J Dermatol. 2016; 43: 389–94

    Article  CAS  PubMed  Google Scholar 

  30. Sato Y et al. S100A7 expression levels in coordination with interleukin-8 indicate the clinical response to infliximab for psoriasis patients. J Dermatol. 2017; 44: 838–9

    Article  PubMed  Google Scholar 

  31. Takahashi T et al. Serum angiopoietin-2 level as a potential biomarker in psoriasis vulgaris. J Dermatol. 2017; 44: 205–6

    Article  CAS  PubMed  Google Scholar 

  32. Davidovici BB et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions. J Invest Dermatol. 2010; 130: 1785–96

    Article  CAS  PubMed  Google Scholar 

  33. Sticherling M. Psoriasis and autoimmunity. Autoimmun Rev. 2016; 15: 1167–70

    Article  CAS  PubMed  Google Scholar 

  34. Prinz JC. Autoimmune aspects of psoriasis: heritability and autoantigens. Autoimmun Rev. 2017; 16: 970–9

    Article  CAS  PubMed  Google Scholar 

  35. Akiyama M et al. Association of psoriasis with Hashimoto’s thyroiditis, Sjögren’s syndrome and dermatomyositis. J Dermatol. 2016; 43: 711–2

    Article  PubMed  Google Scholar 

  36. Maki N et al. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia. J Dermatol. 2016; 43: 571–4

    Article  CAS  PubMed  Google Scholar 

  37. Matsuo H et al. Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: a case report with published work review. J Dermatol. 2017; 44: 826–9

    Article  PubMed  Google Scholar 

  38. Jacobi A, Kupke C, Behzad M, Hertl M. Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. Int J Dermatol. 2013; 52: 1081–7

    Article  PubMed  Google Scholar 

  39. Furue K et al. Autoimmunity and autoimmune co-morbidities in psoriasis. Immunology. 2018; 154: 21–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Gelfand JM et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007; 143: 1493–9

    PubMed  Google Scholar 

  41. Augustin M et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta DermVenereol. 2010; 90: 147–51

    Google Scholar 

  42. Dorschner RA et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol. 2001; 117: 91–7

    Article  CAS  PubMed  Google Scholar 

  43. Nestle FO et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-a production. J Exp Med. 2005; 202: 135–43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007; 449: 564–9

    Article  CAS  PubMed  Google Scholar 

  45. Lowes MA et al. Immunology of psoriasis. Annu Rev Immunol. 2014; 32: 227–55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Teng MW et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015; 21: 719–29

    Article  CAS  PubMed  Google Scholar 

  47. Boniface K et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005; 174: 3695–702

    Article  CAS  PubMed  Google Scholar 

  48. Sa SM et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007; 178: 2229–40

    Article  CAS  PubMed  Google Scholar 

  49. Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidencebased conclusions. J Am Acad Dermatol. 2011; 65: 137–74

    Article  PubMed  Google Scholar 

  50. Jabbar-Lopez ZK et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017; 137: 1646–54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Torii H et al. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study. J Dermatol. 2017; 44: 552–9

    Article  CAS  PubMed  Google Scholar 

  52. Torii H et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016; 43: 767–78

    Article  CAS  PubMed  Google Scholar 

  53. Imafuku S et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016; 43: 1011–7

    Article  CAS  PubMed  Google Scholar 

  54. Asahina A et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study. J Dermatol. 2016; 43: 1257–66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Saeki H et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017; 44: 355–62

    Article  CAS  PubMed  Google Scholar 

  56. Matsumoto A et al. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017; 44: 202–4

    Article  PubMed  Google Scholar 

  57. Hwang YJ et al. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis. J Dermatol. 2017; 44: 560–6

    Article  CAS  PubMed  Google Scholar 

  58. Lande R et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014; 5: 5621

    Article  CAS  PubMed  Google Scholar 

  59. Lande R et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol. 2015; 45: 203–13

    Article  CAS  PubMed  Google Scholar 

  60. Stokkers PC et al. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut. 1999; 45: 395–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Fernando MMA et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008; 4: e1000024

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Gudjonsson JE et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol. 2002; 118: 362–5

    Article  PubMed  Google Scholar 

  63. Gudjonsson JE et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003; 148: 233–5

    Article  CAS  PubMed  Google Scholar 

  64. Plewig G et al. Braun-Falco’s Dermatologie, Venerologie und Allergologie. 6. überarbeitete und erweiterte Auflage. Berlin, Heidelberg: Springer; 2012

    Google Scholar 

  65. Tsai TF et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011; 63: 40–6

    Article  PubMed  Google Scholar 

  66. Wu JJ et al. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012; 67: 924–30

    Article  PubMed  Google Scholar 

  67. Kridin K, Bergman R. Association between bullous pemphigoid and psoriasis: a case-control study. J Am Acad Dermatol. 2017; 77: 370–2

    Article  PubMed  Google Scholar 

  68. Ohata C et al. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases. J Am Acad Dermatol. 2015; 73: 50–5

    Article  PubMed  Google Scholar 

  69. Chen YJ et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011; 165: 593–9

    Article  CAS  PubMed  Google Scholar 

  70. Arunachalam M et al. Non-seg- mental vitiligo and psoriasis comorbidity — a case-control study in Italian patients. J Eur Acad Dermatol Venereol. 2014; 28: 433–7

    Article  CAS  PubMed  Google Scholar 

  71. Blegvad C et al. Autoimmune disease in children and adolescents with psoriasis: a cross-sectional study in Denmark. Acta Derm Venereol. 2017; 97: 1225–29

    Article  PubMed  Google Scholar 

  72. Zhu KJ et al. Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PLoS One. 2011; 6: e23089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995; 32: 982–6

    Article  CAS  PubMed  Google Scholar 

  74. Ludwig RJ et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007; 156: 271–6

    Article  CAS  PubMed  Google Scholar 

  75. Patel RV et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011; 26: 1036–49

    Article  PubMed  PubMed Central  Google Scholar 

  76. Mallbris L et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004; 19: 225–30

    Article  PubMed  Google Scholar 

  77. Gelfand JM et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296: 1735–41

    Article  CAS  PubMed  Google Scholar 

  78. Boehncke WH et al. The ‚psoriatic march‘: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20: 303–7

    Article  PubMed  Google Scholar 

  79. Jacobsson LT et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascuar events in patients with rheumatoid arthritis. J Rheumatol. 2005. 32: 1213–8

    CAS  PubMed  Google Scholar 

  80. Wolk K et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol. 2009; 89: 492–7

    Article  PubMed  Google Scholar 

  81. Setty AR et al. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007; 167: 1670–5

    Article  PubMed  Google Scholar 

  82. Van Kruijsdijk RC et al. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569–78

    Article  PubMed  CAS  Google Scholar 

  83. Gerdes S et al. Adipokines and psoriasis. Exp Dermatol. 2011; 20: 81–7

    Article  CAS  PubMed  Google Scholar 

  84. weltpsoriasistag.de [Internet]. Hamburg: Competenzzentrum Versorgungsforschung in der Dermatologie Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen [zitiert am 22.10.2018]. Verfügbar unter www.weltpsoriasistag.de

  85. Kerscher M. Dermatokosmetik. 2. bearbeitete und erweiterte Auflage. Berlin Hedielberg: Springer; 2009

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Facharzt für Dermatologie und Venerologie, Allergologie, Privatdozent am Universitätsklinikum Hamburg-Eppendorf, Fontenay-Allee 10, 20354, Hamburg, Deutschland

    Arnd Jacobi M.A.

Authors
  1. Arnd Jacobi M.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnd Jacobi M.A..

Additional information

Interessenkonflikt

Der Autor erklärt, dass er sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließ. Der Autor legt folgende potenziellen Interessenkonflikte offen: keine. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die -Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbilds geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jacobi, A. Psoriasis und Komorbidität. ästhet dermatol kosmetol 10, 28–36 (2018). https://doi.org/10.1007/s12634-018-5563-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12634-018-5563-y

Search

Navigation